Combination therapies of TKI with mitogen-activated protein kinase (MEK) inhibitors, angiogenesis inhibitors, and chemotherapy are being evaluated in Phase 1/1b/2 trials mostly in the second-line and beyond treatment settings for the treatment of ALK + NSCLC; a few trials are also evaluating combination therapy in treatment-naive patients42. Here, MAP2K7 is linked to non-small cell lung carcinoma.